Imatinib Mesylate Can Induce Objective Response in Progressing, Highly Expressing KIT Adenoid Cystic Carcinoma of the Salivary Glands
- 1 September 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (25) , 6271-6273
- https://doi.org/10.1200/jco.2005.01.6055
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium StudyJournal of Clinical Oncology, 2005
- Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated casesHead & Neck, 2004
- Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup StudyJournal of Clinical Oncology, 2004
- C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenomaOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2003
- Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinomaCancer Letters, 2000